Retevmo (selpercatinib)

pCPA File Number: 22048

Negotiation Status:

Concluded with an LOI

Indication(s):

Medullary thyroid cancer (MTC), rearranged during transfection (RET)-mutant, in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease

Sponsor/Manufacturer:

Eli Lilly Canada Inc.

CDA-AMC Project Number:

PC0264-000

pCPA Engagement Letter Issued:

2022-11-17

Negotiation Process Concluded:

2023-03-31